category:risks

A new risk? Macular Degeneration

We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.

GLP1.Guide Staff

29 Jun 2025

Here at GLP1.Guide we like to keep an eye out for negative side effects as most of the world is focused on how beneficial GLP1s can be.

🍃

Don't know what a GLP1 Receptor Agonist is, or how drugs like Ozempic, Mounjaro, Wegovy, or Zepbound work?

Check out our quick explainer

A new risk has been flagged in a paper that we found interesting: Macular Degeneration.

Read the rest on Substack

Read more

Kidney injuries on Ozempic

Kidney injuries on Ozempic

Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.

Mounjaro vs Trulicity in a clinical trial

Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.

Medicare/Medicaid might pay for GLP1s again

Medicare/Medicaid might pay for GLP1s again

GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.

Boosting GLP1s with Phentermine

Boosting GLP1s with Phentermine

Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?